For the lower dose range, which affected 70% of myeloma cells or less, a synergistic combination index (CI) below 1 was observed for PDIA1 inhibition combined with BTZ in treatment-naïve MM1.S cells (Figure 3F and Supplemental Figure S3H). This evidence concerns the gene CASC3 and plasma cell myeloma.